Ubs Group Ag Bio N Tech Se Transaction History

Ubs Group Ag

$555 Billion
Q2 2025

A detailed history of Ubs Group Ag transactions in Bio N Tech Se stock. As of the latest transaction made, Ubs Group Ag holds 258,288 shares of BNTX stock, worth $25.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

258,288

Previous 493,931 47.71%

Holding current value

$25.4 Million

Previous $45 Million 38.86%

% of portfolio

0.0%

Previous 0.01%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$86.65 - $120.54 $20.4 Million - $28.4 Million	-235,643 Reduced 47.71%	258,288 $27.5 Million
Q1 2025 May 13, 2025	SELL	$91.06 - $126.88 $3.2 Million - $4.46 Million	-35,122 Reduced 6.64%	493,931 $45 Million
Q4 2024 Feb 14, 2025	BUY	$99.72 - $122.68 $40.5 Million - $49.8 Million	406,072 Added 330.19%	529,053 $60.3 Million
Q3 2024 Nov 14, 2024	SELL	$78.36 - $124.66 $3.34 Million - $5.31 Million	-42,563 Reduced 25.71%	122,981 $14.6 Million
Q2 2024 Aug 13, 2024	BUY	$80.36 - $102.87 $5.9 Million - $7.55 Million	73,416 Added 79.69%	165,544 $13.3 Million
Q1 2024 May 13, 2024	SELL	$88.96 - $112.35 $1.93 Million - $2.43 Million	-21,650 Reduced 19.03%	92,128 $8.5 Million
Q4 2023 Feb 09, 2024	SELL	$90.91 - $112.75 $1.11 Million - $1.38 Million	-12,264 Reduced 9.73%	113,778 $12 Million
Q3 2023 Nov 09, 2023	BUY	$98.5 - $125.08 $2.27 Million - $2.89 Million	23,073 Added 22.41%	126,042 $13.7 Million
Q2 2023 Aug 11, 2023	BUY	$102.58 - $129.66 $1.57 Million - $1.99 Million	15,345 Added 17.51%	102,969 $11.1 Million
Q1 2023 May 12, 2023	SELL	$122.57 - $153.67 $4.79 Million - $6 Million	-39,068 Reduced 30.84%	87,624 $10.9 Million
Q4 2022 Feb 08, 2023	SELL	$118.43 - $186.05 $1.72 Million - $2.71 Million	-14,557 Reduced 10.31%	126,692 $19 Million
Q3 2022 Nov 10, 2022	SELL	$127.65 - $183.11 $4.5 Million - $6.45 Million	-35,224 Reduced 19.96%	141,249 $19.1 Million
Q2 2022 Aug 10, 2022	BUY	$123.25 - $186.24 $670,356 - $1.01 Million	5,439 Added 3.18%	176,473 $26.3 Million
Q1 2022 May 16, 2022	SELL	$126.25 - $231.85 $20.7 Million - $38 Million	-163,839 Reduced 48.93%	171,034 $29.2 Million
Q4 2021 Feb 14, 2022	SELL	$216.64 - $362.52 $3.2 Million - $5.35 Million	-14,758 Reduced 4.22%	334,873 $86.3 Million
Q3 2021 Nov 15, 2021	BUY	$205.93 - $447.23 $8.87 Million - $19.3 Million	43,057 Added 14.04%	349,631 $95.4 Million
Q2 2021 Aug 13, 2021	BUY	$113.32 - $241.49 $2.59 Million - $5.52 Million	22,845 Added 8.05%	306,574 $68.6 Million
Q1 2021 May 12, 2021	BUY	$85.73 - $119.5 $19.7 Million - $27.5 Million	230,057 Added 428.64%	283,729 $31 Million
Q4 2020 Feb 11, 2021	SELL	$72.71 - $129.54 $4.35 Million - $7.76 Million	-59,879 Reduced 52.73%	53,672 $4.38 Million
Q3 2020 Nov 12, 2020	BUY	$57.81 - $104.17 $3.51 Million - $6.32 Million	60,713 Added 114.9%	113,551 $7.86 Million
Q2 2020 Jul 31, 2020	BUY	$38.58 - $66.74 $1.85 Million - $3.2 Million	47,948 Added 980.53%	52,838 $3.53 Million
Q1 2020 May 01, 2020	BUY	$28.55 - $92.0 $109,632 - $353,280	3,840 Added 365.71%	4,890 $286,000
Q4 2019 Feb 14, 2020	BUY	$12.75 - $36.91 $13,387 - $38,755	1,050 New	1,050 $36,000

Others Institutions Holding BNTX

# of Institutions

319

Shares Held

40.9M

Call Options Held

1.38M

Put Options Held

1.52M

View Full List

About BioNTech SE

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $23.8B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

More about BNTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account